How Genetic Changes May Contribute to Pigmentary Glaucoma
Glaucoma can develop quietly, without obvious pain or changes in vision during its early stages. For some people, the condition begins when tiny particles of pigment from the iris interfere with the eye’s natural drainage system, gradually increasing pressure and threatening the optic nerve.
Researchers at Yale School of Medicine have identified additional genetic variations associated with pigmentary glaucoma, providing new clues about why pigment-producing cells may detach from the iris. The findings could help scientists better understand the disease and develop improved approaches to identifying people at risk.
The research was highlighted by Yale School of Medicine on October 27, 2026. The underlying study, published in Ophthalmology Glaucoma on July 27, 2026, examined genetic differences associated with pigment dispersion syndrome and pigmentary glaucoma.
What Is Pigmentary Glaucoma?
Pigmentary glaucoma is a type of glaucoma in which pigment granules released from the iris can obstruct the pathways responsible for draining fluid from the eye. As fluid accumulates, intraocular pressure may rise and damage the optic nerve, which carries visual information from the eye to the brain.
The condition is associated with pigment dispersion syndrome, in which pigment separates from the iris and circulates within the front part of the eye. Not everyone with pigment dispersion syndrome develops glaucoma, but some individuals experience increased eye pressure and progressive optic nerve damage.
This form of glaucoma primarily affects younger adults compared with many other forms of the disease. Its development can involve several factors, including the shape of the eye, inherited genetic differences, and the behavior of cells within the iris.
Understanding these factors matters because optic nerve damage caused by glaucoma is generally irreversible. Detecting increased pressure or early structural damage before significant vision loss occurs can give eye care professionals an opportunity to intervene.
Why Does the Iris Release Pigment?
The iris is the colored structure surrounding the pupil. It regulates how much light enters the eye by changing the size of the pupil, while pigment within its cells helps determine eye color.
In pigment dispersion syndrome, pigment granules can separate from the iris and enter the fluid circulating through the front of the eye. These particles may accumulate in the trabecular meshwork, a network of tissue that helps aqueous humor drain from the eye.
When the drainage system becomes less effective, fluid can build up and increase intraocular pressure. Sustained pressure elevation can contribute to damage of the optic nerve, although some people develop glaucoma even when their measured eye pressure is not unusually high.
Eye anatomy can help explain why pigment is released in certain individuals. However, anatomy alone does not explain every case, which prompted Yale researchers to investigate whether genetic differences might also influence how cells remain attached to surrounding tissue.
What Did Yale Researchers Discover?
The research was led by Mathieu Bakhoum, MD, PhD, an assistant professor of ophthalmology and visual science at Yale School of Medicine. Mark Dibbs, a medical student at Yale, served as the study’s first author.
The team used the National Institutes of Health’s All of Us research program, which collects participants’ health information and genetic data to support medical research. The program had enrolled nearly 750,000 participants at the time described in Yale’s report, representing a broad range of racial and ethnic backgrounds.
Within this resource, the researchers identified more than 500 participants with pigmentary glaucoma or pigment dispersion syndrome. They compared genetic information from these individuals with eye health data from more than 30,000 healthy individuals.
The aim was to identify genetic variants that appeared at different frequencies in the affected group and the comparison group. These differences could point to inherited biological characteristics that influence susceptibility to pigment dispersion or glaucoma.
Two Genetic Methods Helped Reveal New Variants
The investigators used two complementary approaches to examine DNA. The first involved DNA microarrays, which can test hundreds of thousands of selected genetic variants across many participants.
Using this method, the researchers examined nearly 900,000 genetic variants. They also performed whole-genome sequencing, which examines genetic variation across a much broader portion of a person’s DNA, analyzing nearly 13 million variants in total.
Both approaches identified previously reported genetic variants associated with pigment-related biological processes. Importantly, the analyses also revealed new variants that had not been described in earlier studies of pigmentary glaucoma.
One notable finding involved genetic variation near EPHA7, a gene involved in regulating how cells move and interact with neighboring cells. Additional analyses indicated that the identified variant was associated with reduced EPHA7 expression.
This result supports a potential explanation for pigment release: changes in the biological mechanisms that help cells maintain their connections could make it easier for cells or pigment-containing material to separate from the iris. However, the findings do not yet prove that reduced EPHA7 activity directly causes iris pigment loss.
Why EPHA7 Could Be Important
Cells rely on complex molecular signals to maintain their position, communicate with nearby cells, and preserve the structure of tissues. Genes involved in these processes may influence how securely cells remain connected to their surroundings.
Because EPHA7 helps regulate cell movement and interactions, the genetic association offers a possible link between inherited differences and the physical changes observed in pigment dispersion syndrome. It suggests that researchers should investigate not only eye anatomy and pigment production but also the mechanisms controlling cellular attachment.
This is an important distinction. Earlier research had already linked pigmentary glaucoma with changes in genes involved in pigment production. The Yale team’s findings add another potential biological pathway involving how cells maintain their connections.
Further laboratory research will be needed to establish whether EPHA7 directly affects iris cell attachment, how this process operates in living eyes, and whether it contributes to the development of glaucoma in affected individuals.
Could Genetic Findings Improve Glaucoma Screening?
Genetic research may eventually help identify people who have an increased likelihood of developing pigmentary glaucoma before significant optic nerve damage occurs. If scientists can determine which inherited variations are clinically meaningful, those findings could contribute to improved risk assessment and more targeted monitoring.
The study does not establish that a genetic test based on EPHA7 is ready for routine clinical use. A genetic association is an early step in understanding disease risk, and further validation is needed before any individual variant can reliably guide medical decisions.
The All of Us database also demonstrates the value of studying participants with different backgrounds. Genetic studies based on a narrow population may miss important variations or produce findings that do not apply equally to everyone.
Although the research used a large national resource, the number of participants with pigmentary glaucoma or pigment dispersion syndrome was more than 500. Additional studies involving independent populations will help determine how consistently the identified genetic associations appear across different groups.
What Treatments Are Available Today?
Current management of pigmentary glaucoma focuses primarily on lowering intraocular pressure and preventing further damage to the optic nerve. Depending on an individual’s condition, an ophthalmologist may recommend pressure-lowering medication, laser treatment, or surgery.
These approaches can help manage eye pressure, but they do not necessarily stop pigment from separating from the iris. Yale’s report highlights this gap as one reason why understanding the underlying disease mechanisms could be valuable for future treatment development.
Researchers hope that a better understanding of the biological processes responsible for pigment release may eventually lead to therapies that target the disease more directly. Such treatments remain a research goal rather than an established result of the current study.
Symptoms and Tests That Can Help Detect Pigmentary Glaucoma
Pigment dispersion syndrome and pigmentary glaucoma may not cause noticeable symptoms in their early stages. Some individuals experience blurred vision, halos around lights, or temporary visual disturbances, particularly when eye pressure fluctuates. These symptoms are not specific to glaucoma and require appropriate evaluation.
An eye care professional may use tonometry to measure intraocular pressure and gonioscopy to inspect the drainage angle. A slit-lamp examination can help identify pigment deposits, while optic nerve imaging and visual field testing can assess possible damage and changes in vision.
Seek urgent medical attention if you experience sudden severe eye pain, a red eye, sudden blurred vision, halos around lights, or eye symptoms accompanied by nausea and vomiting. These signs may indicate an eye emergency and should not be attributed to pigment dispersion without an examination.
What Happens Next in Pigmentary Glaucoma Research?
The Yale findings provide additional evidence that inherited differences may influence the development of pigmentary glaucoma. The association involving EPHA7 is especially interesting because it points toward cell attachment and movement as potential contributors alongside the pigment-related genetic factors already known.
The research team plans further work to determine whether changes in these cellular mechanisms directly contribute to the disease. That step is essential before the findings can be translated into new diagnostic methods or treatments.
For now, people with a family history of glaucoma, known pigment dispersion syndrome, or previously elevated eye pressure should discuss an appropriate examination schedule with an eye care professional. Regular monitoring can help identify changes before substantial vision loss occurs, while ongoing research continues to clarify how genetics may influence individual risk.
Research source: Dibbs M, Jayaraj C, Martone JF, Bakhoum CY, and Bakhoum MF. “Multi-ancestry genome-wide association with fine-mapping identifies novel loci for pigment dispersion syndrome and pigmentary glaucoma.” Ophthalmology Glaucoma, July 27, 2026. DOI: 10.1016/j.ogla.2026.07.008.
Additional source: Yale School of Medicine’s report on genetic findings in pigmentary glaucoma, published October 27, 2026.
